Markets
Will AI-designed intrabodies be used in clinical trials for Alzheimer's, Parkinson's, or MND by December 31, 2027?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if any AI-designed intrabodies are used in clinical trials for Alzheimer's, Parkinson's, or Motor Neurone Disease by December 31, 2027. To confirm resolution, announcements from reputable research institutions or clinical trial registries will be used.
Rules
- Market closes at 12/31/2027.
- Logic weighted resolution applies.
The odds seem too high for this market. AI-designed intrabodies are still in early research phases and major breakthroughs usually take years to translate to clinical trials, especially for complex diseases like these.
Rationale:The comment accurately reflects the current state of AI-designed intrabodies, noting their early research phase and the typical timeline for breakthroughs in complex diseases, which supports a high Fact Check score. It is logically sound with no fallacies detected, making it relevant to the market question. The emotional appeal is moderate, as it expresses skepticism about the odds, but remains grounded in reasoned argument. The weights reflect the importance of factual accuracy and logical reasoning in this context.
I'm honestly skeptical about this. AI-designed intrabodies are still in early stages of research, and seeing them actually used in clinical trials for these complex neurodegenerative diseases by 2027 seems optimistic. The market's suggesting a pretty high chance, but I wouldn't bet too much on it yet.
Rationale:The comment accurately reflects the current state of AI-designed intrabodies, noting their early research stage and expressing skepticism about their use in clinical trials by 2027. It is relevant to the market question and free from logical fallacies, though it does contain some emotional skepticism. The weights prioritize relevance and logical soundness, given the comment's focus on the market's predictions and the underlying research status.
tbh, I'm a bit skeptical about this market. AI-designed intrabodies are super promising, but clinical trials ain't easy and they take time. By 2027, we might see some progress, but I wouldn't bet the farm on it happening in those areas yet. The uncertainty around regulatory hurdles is a big deal too; I think the price should reflect that.
Rationale:The comment expresses skepticism about the market, highlighting the challenges of clinical trials and regulatory hurdles, which are valid concerns. The factual accuracy is mostly sound, but it lacks specific data to fully support the claims about regulatory hurdles. The comment is logically coherent and relevant to the market question, but it leans slightly on emotional skepticism. The weights reflect the importance of logical reasoning and relevance in this context.
honestly, i think this market is way too optimistic. we've seen some cool stuff coming from ai, but real clinical trials take time and a ton of red tape. plus, the complexity of diseases like alzheimer's and parkinson's means those intrabodies might not be ready by then. i’m not saying it’s impossible, but betting on this happening by the end of 2027 feels like a stretch.
Rationale:The comment presents a mostly accurate perspective on the challenges of bringing AI-designed intrabodies to clinical trials, reflecting on the complexities of diseases like Alzheimer's and Parkinson's. It avoids logical fallacies and remains relevant to the market question, though it could benefit from more specific evidence to support its claims. The weights reflect a balanced emphasis on relevance and logical reasoning, given the speculative nature of the market.
the pricing on this market feels off to me. sure, there’s a lot of promise with AI-designed intrabodies, but we still haven't seen enough reliable data come out of trials yet. if we look back at past developments in neurodegenerative diseases, like how long it took for anything meaningful to come out for ALS, it’s clear this could drag out a lot longer than 2027. plus, even if they make it to clinical trials, there's always that big chance they won't be effective. it's not a sure thing. so either this price is a bit too optimistic, or i’m just way too cynical.
Rationale:The comment presents a mostly accurate perspective on the uncertainty surrounding AI-designed intrabodies, particularly in the context of neurodegenerative diseases, which is relevant to the market question. While it acknowledges the promise of AI, it also highlights the lack of reliable data and the historical context of slow progress in similar fields. The weights reflect a balanced focus on relevance and logical reasoning, with some emotional elements present. Overall, the comment is thoughtful and engages with the market topic effectively.
honestly, i see a lot of potential here with AI tech advancing rapidly. but betting on this market might be a stretch, considering clinical trials can take years to show results. right now, i’d say it’s overpriced; maybe 30% chance by end of 2027.
Rationale:The comment presents a reasonable perspective on the potential of AI technology while acknowledging the lengthy nature of clinical trials, which is a valid point. However, the claim of a 30% chance lacks specific evidence or data to support it, leading to a slightly lower score in Fact Check. The weights reflect a balanced focus on relevance and logical reasoning, given the speculative nature of the market.
the tech is crazy advanced but the timeline for trials is always way longer than people expect, seems like a risky bet to me.
Rationale:The comment accurately reflects the common perception that timelines for clinical trials can be longer than anticipated, which is a reasonable observation. However, it lacks specific evidence to support the claim about the technology's advancement and the associated risks. The weights reflect a balanced focus on relevance and logical reasoning, given the comment's speculative nature about timelines and risks.
the price on this feels way too optimistic, we've seen a ton of hype around AI in medicine but actual results? still waiting.
Rationale:The comment expresses skepticism about the optimism surrounding AI in medicine, which is a relevant perspective for the market question. While it accurately reflects a general sentiment about hype versus results, it lacks specific evidence to support the claim of 'waiting' for actual results, leading to a score of 70 for Fact Check. The comment is logically sound with no major fallacies, but it does lean slightly on emotional appeal, hence the balanced scores across the criteria.
tbh, idk why this price is so high, like we've seen a bunch of ai stuff just stall out in trials before, especially for neuro stuff.
Rationale:The comment raises valid concerns about the historical challenges faced by AI technologies in clinical trials, particularly in neurology, which is a relevant point. However, it lacks specific evidence or data to support the claim about the price being high, leading to a score of 70 for Fact Check. The comment is mostly logical and relevant, but it does contain some emotional elements regarding skepticism about AI advancements, justifying a moderate score in Logic/Emotion balance.
tbh, I’m not sold on this one. Like, sure AI is making waves, but clinical trials take ages and there are so many hurdles. I feel like the price is overhyped right now.
Rationale:The comment expresses skepticism about the use of AI-designed intrabodies in clinical trials, which is a relevant perspective. However, it lacks specific factual support for its claims about the timeline and hurdles, leading to a mixed score for Fact Check. The comment is mostly logical but contains some emotional elements, hence the moderate scores in Logic/Emotion and No Fallacies. The weights reflect the importance of relevance and logical reasoning in this context.